Testing was performed at abbott diagnostics (b)(4) inc.On retained kit lot 119305 with the following internal serum/plasma samples: (b)(6), p24 (b)(6), and (b)(6).All test results were valid and performed as expected.Additionally, the manufacturing batch records for lot 119305 were reviewed.This lot met the required release specifications.A review of the complaints reported as (b)(6) (including confirmed, unconfirmed, and conflicting) related to lot number 119305 showed that the complaint rate is (b)(6).The evidence available does not indicate that the product is performing outside label claims.Alere (b)(4) was unable to determine the exact root cause of the reported issue.The results obtained may possibly be related to the patient sample.The sample may have contained specific substances which may have affected the results.The available evidence suggests that this device lot is performing within labeled claims.
|
The customer reported 13 (b)(6) results with the alere determine (b)(6) ½ ag/ab combo test.The customer stated that the sample type "majority" was serum, "sometimes" edta plasma (numbers of each sample type not provided).The customer also stated that "most" of the (b)(6) results were for antibodies (results not further specified).Confirmation testing performed with centaur 4th generation provided negative results.The customer was unable to provide further details regarding the alere determine (b)(6) ½ ag/ab test.Attempts to gain further information were unsuccessful.The customer confirmed there was no death or serious injury based on the results.The customer stated that "many" of the patients were pregnant and labor and delivery patients (not further specified).No further patient information, including art treatment, impact, and outcome, was provided.Per the alere determine (b)(6) -1/2 ag/ab combo product insert limitations: ·a reactive result using alere determine (b)(6) -1/2 ag/ab combo suggests the presence of (b)(6) p24 antigen and/or antibodies to (b)(6) in the sample.The reactive result is interpreted as preliminary (b)(6) for (b)(6) p24 antigen and/or antibodies to (b)(6) and/or (b)(6).Alere determine (b)(6)-1/2 ag/ab combo is intended as aid in the diagnosis of infection with (b)(6) 1/2.·specimens from individuals with toxoplasma igg, human anti-mouse antibodies, rheumatoid factor, elevated triglycerides (above 600 mg/dl), (b)(6) virus infection, hospitalized and cancer patients may give (b)(6) test results.
|